These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 19750589)

  • 1. Immunotherapy with dendritic cells pulsed by autologous dactinomycin-induced melanoma apoptotic bodies for patients with malignant melanoma.
    Chang JW; Hsieh JJ; Shen YC; Ho E; Chuang CK; Chen YR; Liao SK; Chen JS; Leong SP; Hou MM; Chang NJ; Wang CH
    Melanoma Res; 2009 Oct; 19(5):309-15. PubMed ID: 19750589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma.
    Redman BG; Chang AE; Whitfield J; Esper P; Jiang G; Braun T; Roessler B; Mulé JJ
    J Immunother; 2008; 31(6):591-8. PubMed ID: 18528294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immature human monocyte-derived dendritic cells migrate rapidly to draining lymph nodes after intradermal injection for melanoma immunotherapy.
    Thomas R; Chambers M; Boytar R; Barker K; Cavanagh LL; MacFadyen S; Smithers M; Jenkins M; Andersen J
    Melanoma Res; 1999 Oct; 9(5):474-81. PubMed ID: 10596914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.
    Nestle FO; Alijagic S; Gilliet M; Sun Y; Grabbe S; Dummer R; Burg G; Schadendorf D
    Nat Med; 1998 Mar; 4(3):328-32. PubMed ID: 9500607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.
    Geiger JD; Hutchinson RJ; Hohenkirk LF; McKenna EA; Yanik GA; Levine JE; Chang AE; Braun TM; Mulé JJ
    Cancer Res; 2001 Dec; 61(23):8513-9. PubMed ID: 11731436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
    Lesterhuis WJ; de Vries IJ; Schreibelt G; Lambeck AJ; Aarntzen EH; Jacobs JF; Scharenborg NM; van de Rakt MW; de Boer AJ; Croockewit S; van Rossum MM; Mus R; Oyen WJ; Boerman OC; Lucas S; Adema GJ; Punt CJ; Figdor CG
    Clin Cancer Res; 2011 Sep; 17(17):5725-35. PubMed ID: 21771874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.
    Banchereau J; Palucka AK; Dhodapkar M; Burkeholder S; Taquet N; Rolland A; Taquet S; Coquery S; Wittkowski KM; Bhardwaj N; Pineiro L; Steinman R; Fay J
    Cancer Res; 2001 Sep; 61(17):6451-8. PubMed ID: 11522640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer.
    Chang AE; Redman BG; Whitfield JR; Nickoloff BJ; Braun TM; Lee PP; Geiger JD; Mulé JJ
    Clin Cancer Res; 2002 Apr; 8(4):1021-32. PubMed ID: 11948109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma.
    Kim JH; Lee Y; Bae YS; Kim WS; Kim K; Im HY; Kang WK; Park K; Choi HY; Lee HM; Baek SY; Lee H; Doh H; Kim BM; Kim CY; Jeon C; Jung CW
    Clin Immunol; 2007 Dec; 125(3):257-67. PubMed ID: 17916447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination of Japanese patients with advanced melanoma with peptide, tumor lysate or both peptide and tumor lysate-pulsed mature, monocyte-derived dendritic cells.
    Nakai N; Asai J; Ueda E; Takenaka H; Katoh N; Kishimoto S
    J Dermatol; 2006 Jul; 33(7):462-72. PubMed ID: 16848818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial).
    Ridolfi L; de Rosa F; Fiammenghi L; Petrini M; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Bulgarelli J; Riccobon A; Gentili G; Nanni O; Framarini M; Tauceri F; Guidoboni M
    BMJ Open; 2018 Aug; 8(8):e021701. PubMed ID: 30082356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate.
    Vilella R; Benítez D; Milà J; Lozano M; Vilana R; Pomes J; Tomas X; Costa J; Vilalta A; Malvehy J; Puig S; Mellado B; Martí R; Castel T
    Cancer Immunol Immunother; 2004 Jul; 53(7):651-8. PubMed ID: 14999431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer.
    Iwashita Y; Tahara K; Goto S; Sasaki A; Kai S; Seike M; Chen CL; Kawano K; Kitano S
    Cancer Immunol Immunother; 2003 Mar; 52(3):155-61. PubMed ID: 12649744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.
    Lesimple T; Neidhard EM; Vignard V; Lefeuvre C; Adamski H; Labarrière N; Carsin A; Monnier D; Collet B; Clapisson G; Birebent B; Philip I; Toujas L; Chokri M; Quillien V
    Clin Cancer Res; 2006 Dec; 12(24):7380-8. PubMed ID: 17189411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
    Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
    J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma.
    Lau R; Wang F; Jeffery G; Marty V; Kuniyoshi J; Bade E; Ryback ME; Weber J
    J Immunother; 2001; 24(1):66-78. PubMed ID: 11211150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cell-based vaccination in solid cancer.
    Stift A; Friedl J; Dubsky P; Bachleitner-Hofmann T; Schueller G; Zontsich T; Benkoe T; Radelbauer K; Brostjan C; Jakesz R; Gnant M
    J Clin Oncol; 2003 Jan; 21(1):135-42. PubMed ID: 12506182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of Th1 response by dendritic cells pulsed with autologous melanoma apoptotic bodies.
    Chang JW; Peng M; Vaquerano JE; Zhou YM; Clinton RA; Hyun WC; Giedlin MA; Leong SP
    Anticancer Res; 2000; 20(3A):1329-36. PubMed ID: 10928040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor.
    Chang AE; Li Q; Bishop DK; Normolle DP; Redman BD; Nickoloff BJ
    Hum Gene Ther; 2000 Apr; 11(6):839-50. PubMed ID: 10779161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.